A comparative study on concurrent chemoradiation using cisplatin versus carboplatin in the management of locoregionally advanced non-small cell lung cancer
Keywords:Carboplatin, Cisplatin, Concurrent chemoradiation, Locoregionally advanced non-small cell lung cancer
Background: Concurrent chemoradiation is considered the standard care for locoregionally advanced non-small cell lung cancer. This study aimed to compare the treatment response, progression free survival and treatment toxicities between cisplatin and carboplatin based concurrent chemoradiation.
Methods: Between October 2015 and September 2017, 60 eligible patients were enrolled and divided into two arms of 30 patients each. Arm A received EBRT to chest (60Gy/30 fractions) with concurrent weekly Injection Cisplatin 35mg/m2. Arm B received EBRT to chest (60Gy/30 fractions) with concurrent weekly Injection Carboplatin at a dose of AUC-2. Early treatment response was assessed at 1 month and late treatment response at 6 months after completion of radiation using RECIST criteria. Treatment toxicities was assessed using RTOG toxicity criteria. All statistical analysis was carried out using SPSS version 21.
Results: Most patients were in the age range of 61-70 years. Mean age of presentation was 67.53±11.038 years in Arm A and 66.03±12.794 years in Arm B. Median follow up was 16 months for both arms. Response rate of was slightly better in Arm A (73.3% versus 60%). 1 year PFS rate was 53.33% in Arm A and 36.67% in Arm B. Median time to progression was better in Arm A (11 months vs 10 months). Toxicities were almost comparable in both the arms.
Conclusions: Use of carboplatin in combination with radiation therapy is comparable to cisplatin in terms of treatment outcomes with better compliance and lower toxicity.
Rengan R, Chetty IJ, Decker R, Langer CJ, O’Meara WP, Movsas B. Lung cancer. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez and Brady’s Principles And Practice of Radiation Oncology. 6th ed. PA: Lippincott Williams and Wilkins; 2013:938-939.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83(3):355-67.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics. CA Cancer J Clin. 2008;58(2):71-96.
Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1):21-49.
Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987;59:1874-81.
Hotta K, Kuira K. Role of platinum based radiochemotherapy for locally advanced non-small cell lung cancer: Possible influence of type of platinum on survival data. Ann Oncol. 2006;17(11):1724.
Marcu LG. Improving Therapeutic ratio in head and neck cancer with adjuvant and Cisplatin based treatments. Biomed Res Int. 2013;817279:1-4.
Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW et al. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 2013;18(7):843-.9
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692-9.
Gervais R, Ducolone A, Lechevalier T, Legroumellec A, Lemarie E, Quoix E et al. Conventional radiation with daily carboplatin (Cb) compared to RT alone after induction chemotherapy(ICT) [vinorelbine (Vr)-cisplatin (P)]: Final results of a randomized phase III trial in stage III unresectable non-small cell lung cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol. 2005;23(16):7016-7.
Lechevalier T, Arriagada R, Quoix E, Ruffle P, Martin M, Tarayre M et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomised trial in 353 patients. J Natl Cancer Inst. 1991;83:417-23.
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC,, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Eng J Med. 1990;323(14):940-5.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899-909.
Pinedo HM, Karim ABMF, van Vliet WH, Snow JB, Vermorken JB. Daily cis-dichlorodiammineplatinum (II) as a radio-enhancer: a preliminary toxicity report. J Cancer Res Clin Oncol. 1983;105:79-82.
Auperin A, Pechoux CL, Pignon JP, Koning C, Jeremic B, Clamon G et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17(3):473-83.
Clamon G, HerndonJ, Eaton W, Rosenman J, Maurer LH, Cooper MR et al. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: A phase II trial of Cancer and Leukemia Group B. Cancer Invest. 1994;12(3):273- 82.
Patterson CJ, Hocking M, Bond M, Teale C. Retrospective study for lung cancer in patients aged 75 years and over. Age Ageing. 1998;27(4):515-8.
Fairchild A, Harris K, Barnes E, Wong R, Lutz ST, Bezjak A et al. Palliative Thoracic Radiotherapy for Lung Cancer: A Systematic Review. J Clin Oncol. 2008;26(24): 4001-11.
Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999;52:129-36.
Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998;16:3078-81.
Belderbos J, Uitterhoeve L., van Zandwijk L, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007;43:114-21.
Pradier O, Lederer K, Hille A, Weiss E, Christiansen H, Schmidberger H et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol. 2005;131:261-9.
Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol. 1995;13:1425-9
Bahl A, Sharma DN, Julka PK, Rath GK. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. J Cancer Res Ther. 2006;2:14-6.
Çakir Ş, Yücel İ , Egehan İ , Küçükpilakçi B , Soylu B, Elgin Y et al. Radiotherapy versus radiotherapy enhanced by cisplatin in inoperable nonmetastatic nonsmall cell lung cancer (NSCLC) : Preliminary Results Of a Randomized Study. Radiother Oncol. 1996;40:S151.
Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524-3.
Gouda YS, Kohail HM, Eldeeb NA, Omar AM, El-Geneidy MM, Elkerm YM. Randomized study of concurrent carboplatin, paclitaxel, and radiotherapy with or without prior induction chemotherapy in patients with locally advanced non-small cell lung cancer. J Egypt Natl Canc Inst. 2006;18(1):73-81.
Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al. Sequential versus concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-60.
Crino L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small cell lung cancer: ESMO Clinical practical guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;21(5):103-15.
Trovó MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24(1):11-5.
Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer. 2004;43:309-16.
Ichinose Y, Nakai Y, Kudoh S, Semba H, Yoshida S, Nukiwa T et al. Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004;10:4369-73.
Groen HJ, van der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol. 2004;15:427-32.
Vokes EE, Herndon J.E, Kelley M.J, Cicchetti MG, Ramnath N, Neill H et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: cancer and Leukemia Group. B J Clin Oncol. 2007;25:1698-704.